drugset / Trial / NCT07490535
This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye
Phase 4
Not yet recruiting
36 enrolled
Pittsburgh Research Institute
Bausch & Lomb Incorporated · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a single-center prospective open-label, clinical trial to explore proteomic expression of tear fluid biomarkers in patients with dry eye treated with Lifitegrast.
Timeline
- Start
- 2026-03
- Primary completion
- 2026-09
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lifitegrast | Unknown | 5 % | — |